Satsuma Pharmaceuticals Announces FDA Acceptance of 505 NDA for STS101, a Novel and Investigational Dihydroergotamine Nasal Powder Product for the Acute Treatment of Migraine
STSADelisted Stock | USD 1.10 0.01 0.90% |
About 61% of Satsuma Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Satsuma Pharmaceuticals suggests that many traders are alarmed regarding Satsuma Pharmaceuticals' prospects. The current market sentiment, together with Satsuma Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Satsuma Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Satsuma |
January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial against modern outcome measures recommended by both the U.S.
Read at benzinga.com
Satsuma Pharmaceuticals Fundamental Analysis
We analyze Satsuma Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Satsuma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Satsuma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Satsuma Pharmaceuticals is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Satsuma Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Satsuma Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Satsuma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Satsuma Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Satsuma Pharmaceuticals Related Equities
FBRX | Forte Biosciences | 9.70 | ||||
CTMX | CytomX Therapeutics | 3.92 | ||||
CING | Cingulate | 3.81 | ||||
MNOV | MediciNova | 2.99 | ||||
CYCN | Cyclerion Therapeutics | 1.85 | ||||
ASMB | Assembly Biosciences | 1.25 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
ADXN | Addex Therapeutics | 1.04 | ||||
ACHL | Achilles Therapeutics | 0.93 | ||||
SNTI | Senti Biosciences | 0.93 | ||||
PEPG | PepGen | 0.98 | ||||
KRON | Kronos Bio | 1.04 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
ERAS | Erasca | 2.05 | ||||
PHVS | Pharvaris | 2.06 | ||||
LRMR | Larimar Therapeutics | 4.67 | ||||
TIL | Instil Bio | 9.39 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Satsuma Stock
If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |